<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang R</submitter><funding>National Natural Science Foundation of China</funding><pagination>4859-4871</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9465192</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>26(18)</volume><pubmed_abstract>RNA-binding Motif Protein39 (RBM39) is identified as a splicing factor and transcription coactivator. Despite mounting evidence that RBM39 plays a critical role in the development of specific malignancies, no systematic pan-cancer investigation of RBM39 has been conducted. As a result, we set out to investigate RBM39's prognostic significance and putative immunological activities in 33 different cancers. Based on TCGA and CCLE, GTEx, cBioportal and HPA, we used a series of bioinformatics approaches to explore the potential oncogenic role of RBM39, including analysis of the expression of the pan-cancer species RBM39, the prognostic relationship between RBM39 expression and overall survival (OS), disease-specific survival (DSS) and progression-free interval (PFI), the relationship between RB</pubmed_abstract><journal>Journal of cellular and molecular medicine</journal><pubmed_title>Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker.</pubmed_title><pmcid>PMC9465192</pmcid><funding_grant_id>81972165</funding_grant_id><funding_grant_id>81972845</funding_grant_id><pubmed_authors>Liu N</pubmed_authors><pubmed_authors>Zhang N</pubmed_authors><pubmed_authors>Wang W</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Zhang R</pubmed_authors><pubmed_authors>Liu W</pubmed_authors></additional><is_claimable>false</is_claimable><name>Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker.</name><description>RNA-binding Motif Protein39 (RBM39) is identified as a splicing factor and transcription coactivator. Despite mounting evidence that RBM39 plays a critical role in the development of specific malignancies, no systematic pan-cancer investigation of RBM39 has been conducted. As a result, we set out to investigate RBM39's prognostic significance and putative immunological activities in 33 different cancers. Based on TCGA and CCLE, GTEx, cBioportal and HPA, we used a series of bioinformatics approaches to explore the potential oncogenic role of RBM39, including analysis of the expression of the pan-cancer species RBM39, the prognostic relationship between RBM39 expression and overall survival (OS), disease-specific survival (DSS) and progression-free interval (PFI), the relationship between RB</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-04-04T03:34:11.868Z</modification><creation>2025-04-04T03:34:11.868Z</creation></dates><accession>S-EPMC9465192</accession><cross_references><pubmed>35989423</pubmed><doi>10.1111/jcmm.17517</doi></cross_references></HashMap>